World J Mens Health.  2013 Apr;31(1):47-52.

Testosterone Replacement Alone for Testosterone Deficiency Syndrome Improves Moderate Lower Urinary Tract Symptoms: One Year Follow-Up

• Ko YH
• Moon DG
• Moon KH

Abstract

PURPOSE
To evaluate the actual impact of testosterone replacement therapy (TRT) on patients with lower urinary tract symptom (LUTS), without benign prostate hyperplasia (BPH) medication.
MATERIALS AND METHODS
Two hundreds forty-six patients underwent TRT using intramuscular injection of 3 months bases injection of testosterone 100 mg undecanoate over a year. Among them, 17 patients had moderate LUTS with a maximal flow rate of at least 10 ml/s but did not take any BPH-specific medication during TRT. The changes in prostate specific antigen (PSA), International Prostate Symptom Score (IPSS), and uroflowmetery were measured before and after TRT.
RESULTS
After TRT, PSA remained unchanged after a year of treatment (p=0.078). Compared with their counterparts (n=229), the patients without BPH medication had similar baseline prostate characteristics in all variables, including prostate volume, IPSS, maximal flow rate, voiding volume, and PSA, except the median amount of residual urine, which was higher in the patients without BPH medication (21 ml vs. 10 ml). In the no-BPH medication group, the total IPSS score was decreased significantly (p=0.028), both in storage symptoms (questionnaire 2, 4, 7) and voiding symptoms (questionnaire 1, 3, 5, 6), while the maximal flow rate and residual urine amount remained unchanged after a year of TRT. During the median follow up of 15.1 months, no patients experienced urinary retention, BPH-related surgery, or admission for urinary tract infection.
CONCLUSIONS
Over a year of TRT for the no-BPH medication patients with moderate LUTS and maintained a relatively high maximal flow rate and improved both storage and voiding symptoms, without the clinical progression of BPH or rising PSA.

Keyword

Androgen analogues; Prostatic hyperplasia; Lower urinary tract symptoms

MeSH Terms

Follow-Up Studies
Humans
Hyperplasia
Injections, Intramuscular
Lower Urinary Tract Symptoms
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Testosterone
Testosterone Congeners
Urinary Retention
Urinary Tract
Prostate-Specific Antigen
Testosterone
Testosterone Congeners

Reference

1. Park NC, Seo JT, Moon KH, Park K, Park JK, Park HJ. Efficacy and safety of testosterone gel in Korean men with late-onset hypogonadism: a prospective, fixed-dose, placebo-uncontrolled, open-label, multicenter study. Korean J Androl. 2007; 25:103–111.

2. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2005; 8:56–58. PMID: 16096159.

3. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, et al. The Prostate Study Group of the Austrian Society of Urology. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. Urology. 2000; 55:397–402. PMID: 10699620.

4. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007; 69:708–713. PMID: 17445656.

5. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009; 5:427–448. PMID: 19707253.

6. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992; 75:1092–1098. PMID: 1400877.

7. Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993; 23:99–106. PMID: 7690956.

8. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006; 296:2351–2361. PMID: 17105798.

9. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011; 14:53–58. PMID: 21171937.

10. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010; 57:123–131. PMID: 19825505.

11. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006; 97(Suppl 2):23–28. PMID: 16507050.

12. Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male. 2008; 11:51–55. PMID: 18570055.

13. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol. 2003; 170:2517–2522. PMID: 14634463.

14. Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL, et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril. 1995; 63:1101–1107. PMID: 7536692.

15. Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008; 11:146–149. PMID: 18821291.

16. Celayir S. Effects of different sex hormones on male rabbit urodynamics: an experimental study. Horm Res. 2003; 60:215–220. PMID: 14614225.

17. Madeiro A, Girão M, Sartori M, Acquaroli R, Baracat E, Rodrigues De Lima G. Effects of the association of androgen/estrogen on the bladder and urethra of castrated rats. Clin Exp Obstet Gynecol. 2002; 29:117–120. PMID: 12171313.

18. Cayan F, Tek M, Balli E, Oztuna S, Karazindiyanoğlu S, Cayan S. The effect of testosterone alone and testosterone + estradiol therapy on bladder functions and smooth muscle/collagen content in surgically menopause induced rats. Maturitas. 2008; 60:248–252. PMID: 18774243.